Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mezzion-pharma-co-ltd" target="_blank" data-smartkarma-citation="entities:11423:1" rel="noopener">Mezzion Pharma (140410 KS)</a> was added to the Investment Attention Issue list on 17 March and traded down 21%. Then came the announcement of the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ 150 Index</a> deletion.</li>
<li>As the highest ranked non-constituent from the Healthcare sector at the December rebalance, Curiox BioSystems (445680 KQ) will be added to the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ150 Index</a> at the close on 19 March.</li>
<li>Historically, intra-review inclusions have moved higher between announcement and implementation and there has been reversion post the index inclusion.</li>
</ul>



Mezzion Pharma (140410 KS) was added to the Investment Attention Issue list on 17 March and traded down 21%. Then came the announcement of the KOSDAQ 150 Index deletion.
As the highest ranked non-constituent from the Healthcare sector at the December rebalance, Curiox BioSystems (445680 KQ) will be added to the KOSDAQ150 Index at the close on 19 March.
Historically, intra-review inclusions have moved higher between announcement and implementation and there has been reversion post the index inclusion.


KOSDAQ150 Index Adhoc Rebalance: Curiox Bio (445680 KQ) To Replace Mezzion Pharma (140410 KQ)

Director, Head of Research, Smartkarma

Pranav Rao

Director, Head of Research

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

CapitaLand India Trust / Equity Capital Markets

<ul>
<li>Welcome to Curator’s Cut - a fortnightly roundup of standout themes from the 1,300+ insights published on Smartkarma.</li>
<li>In this cut, we examine why opportunities exist in Korea despite the record rally, look at the rush of shareholders trimming APAC stakes, and welcome coverage on 500+ private companies.</li>
<li>Want to dig deeper? Comment or message with the themes you’d like to see highlighted next.</li>
</ul>


Welcome to Curator’s Cut - a fortnightly roundup of standout themes from the 1,300+ insights published on Smartkarma.
In this cut, we examine why opportunities exist in Korea despite the record rally, look at the rush of shareholders trimming APAC stakes, and welcome coverage on 500+ private companies.
Want to dig deeper? Comment or message with the themes you’d like to see highlighted next.


Curator's Cut: Seoul Searching Redux, APAC Placements Apace & More Private Markets Coverage

Event-Driven

<ul>
<li>On 6 November, <a href="https://www.smartkarma.com/entities/alteogen-inc" target="_blank" data-smartkarma-citation="entities:15886:1" rel="noopener">Alteogen Inc (196170 KS)</a>'s Board approved the delisting of the stock from the KOSDAQ market and the listing on the KOSPI market. Shareholders approved on 8 December.</li>
<li>
<a href="https://www.smartkarma.com/entities/alteogen-inc" target="_blank" data-smartkarma-citation="entities:15886:1" rel="noopener">Alteogen</a> has not yet applied to the KRX for the listing change. While the listing transfer approval had historically taken around 2-3 months, there have been no approvals recently.</li>
<li>
<a href="https://www.smartkarma.com/entities/alteogen-inc" target="_blank" data-smartkarma-citation="entities:15886:1" rel="noopener">Alteogen</a> will be deleted from the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ150 Index</a> on its last trading day and inclusion in the <a href="https://www.smartkarma.com/entities/korea-stock-exchange-kospi-200" target="_blank" data-smartkarma-citation="entities:26021:1" rel="noopener">KOSPI200 Index</a> will take place at the next regular rebalance (or earlier).</li>
</ul>


On 6 November, Alteogen Inc (196170 KS)'s Board approved the delisting of the stock from the KOSDAQ market and the listing on the KOSPI market. Shareholders approved on 8 December.

Alteogen has not yet applied to the KRX for the listing change. While the listing transfer approval had historically taken around 2-3 months, there have been no approvals recently.

Alteogen will be deleted from the KOSDAQ150 Index on its last trading day and inclusion in the KOSPI200 Index will take place at the next regular rebalance (or earlier).


Alteogen (196170 KS): Index Impact of KOSDAQ to KOSPI Transfer

<ul>
<li>There will be 16 changes for the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ 150 Index (KOSDQ150 INDEX)</a> at the next rebalance to be implemented at the close on 11 December.</li>
<li>Making use of their discretionary powers, the index committee has not added <a href="https://www.smartkarma.com/entities/wonik-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:6485:1" rel="noopener">Wonik Holdings Co., Ltd (030530 KS)</a>, <a href="https://www.smartkarma.com/entities/samhyun-co-ltd" target="_blank" data-smartkarma-citation="entities:40872:1" rel="noopener">Samhyun (437730 KS)</a> and <a href="https://www.smartkarma.com/entities/fadu-inc" target="_blank" data-smartkarma-citation="entities:39896:1" rel="noopener">Fadu (440110 KS)</a> to the index.</li>
<li>The adds have outperformed the deletes and the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ 150 Index</a> over the last 6 months and there has been a short-term move higher too. Watch out for short covering.</li>
</ul>


There will be 16 changes for the KOSDAQ 150 Index (KOSDQ150 INDEX) at the next rebalance to be implemented at the close on 11 December.
Making use of their discretionary powers, the index committee has not added Wonik Holdings Co., Ltd (030530 KS), Samhyun (437730 KS) and Fadu (440110 KS) to the index.
The adds have outperformed the deletes and the KOSDAQ 150 Index over the last 6 months and there has been a short-term move higher too. Watch out for short covering.


KOSDAQ150 Index Rebalance: 16 Changes a Side; Fadu a Casualty Yet Again

<ul>
<li>With the review period for the December rebalance complete, we highlight 17 potential changes for the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ 150 Index (KOSDQ150 INDEX)</a>. </li>
<li>The estimated impact on the potential inclusions ranges from 0.1-3.2 days of ADV while the impact on the potential deletions varies from 0.7-11.2 days of ADV.</li>
<li>The forecast adds have outperformed the forecast deletes over the last 6 months with a big move higher in the last couple of months. Trim positions into strength.</li>
</ul>


With the review period for the December rebalance complete, we highlight 17 potential changes for the KOSDAQ 150 Index (KOSDQ150 INDEX). 
The estimated impact on the potential inclusions ranges from 0.1-3.2 days of ADV while the impact on the potential deletions varies from 0.7-11.2 days of ADV.
The forecast adds have outperformed the forecast deletes over the last 6 months with a big move higher in the last couple of months. Trim positions into strength.


KOSDAQ150 Index Rebalance Preview: Large Number of Changes Likely in December; Huge Outperformance

South Korea

KOSDAQ 150 Index is a base index for futures trading to hedge risks in KOSDAQ market. Base period and base index : Jan 4, 2010, 1,000p

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

KOSDAQ 150 Index (KOSDQ150 INDEX EQUITY)

KOSDAQ150 Index Adhoc Rebalance: Curiox Bio (445680 KQ) To Replace Mezzion Pharma (140410 KQ)

Mezzion Pharma has been added to the Investment Attention list and will be deleted from the KOSDAQ150 Index. Curiox Biosystems will be added to the...

Brian Freitas

Curator's Cut: Seoul Searching Redux, APAC Placements Apace & More Private Markets Coverage

This Curator's Cut issue highlights opportunities in Korea amidst the record rally, shareholder stake trimming in APAC, and coverage on 500+...

Pranav Rao

Alteogen (196170 KS): Index Impact of KOSDAQ to KOSPI Transfer

Alteogen's shareholders have approved the KOSDAQ to KOSPI transfer. Given recent delays, the timeline could be long drawn out. KOSPI200 buying will...

Brian Freitas

KOSDAQ150 Index Rebalance: 16 Changes a Side; Fadu a Casualty Yet Again

There are 16 changes a side for the KOSDAQ150 in Dec. The index committee has decided not to add Fadu for yet another review. Short interest is...

Brian Freitas

KOSDAQ150 Index Rebalance Preview: Large Number of Changes Likely in December; Huge Outperformance

There could be 17 changes for the KOSDAQ150 Index in Dec. Use of discretion could lead to fewer changes. The forecast adds have hugely outperformed...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

KOSDAQ150 Index Adhoc Rebalance: Curiox Bio (445680 KQ) To Replace Mezzion Pharma (140410 KQ)

Mezzion Pharma has been added to the Investment Attention list and will be deleted from the KOSDAQ150 Index. Curiox Biosystems will be added to the...

Brian Freitas

Curator's Cut: Seoul Searching Redux, APAC Placements Apace & More Private Markets Coverage

This ​Curator's Cut issue highlights opportunities in Korea amidst the record rally, shareholder stake trimming in APAC, and coverage on 500+...

Pranav Rao

Alteogen (196170 KS): Index Impact of KOSDAQ to KOSPI Transfer

Alteogen's shareholders have approved the KOSDAQ to KOSPI transfer. Given recent delays, the timeline could be long drawn out. KOSPI200 buying will...

Brian Freitas

KOSDAQ150 Index Rebalance: 16 Changes a Side; Fadu a Casualty Yet Again

There are 16 changes a side for the KOSDAQ150 in Dec. The index committee has decided not to add Fadu for yet another review. Short interest is...

Brian Freitas

KOSDAQ150 Index Rebalance Preview: Large Number of Changes Likely in December; Huge Outperformance

There could be 17 changes for the KOSDAQ150 Index in Dec. Use of discretion could lead to fewer changes. The forecast adds have hugely outperformed...

Brian Freitas

This Curator's Cut issue highlights opportunities in Korea amidst the record rally, shareholder stake trimming in APAC, and coverage on 500+...